Glaukos Licenses RevOpsis Retinal Biologic RO-104 and RevMod Platform

Zacks Investment Research·9 Oct 2026·

·Read original

3▲1 ▼0Impact / 5

M&A · Partnership Product / Tech Health Care Equipment & Supplies

GKOS ▲

Summary · why it matters

Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop and commercialize RO-104, an investigational tri-specific biologic for multiple retinal diseases, while gaining exclusive rights to the RevMod platform to discover and develop up to four additional retinal biologic candidates. RO-104 is a first-in-class tri-specific biologic with a high-concentration formulation that inhibits VEGF-A, VEGF-C and Ang-2, three clinically validated pathways involved in retinal vascular diseases, and is being developed for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. In established preclinical animal models, the candidate demonstrated superior efficacy compared with approved anti-VEGF therapies, and the license covers the RevMod platform across geographic atrophy, DME, DR, RVO and nAMD. Chairman and CEO Thomas Burns said the addition of RO-104 and exclusive access to the RevMod platform marks a strategic step in expanding the company's retinal franchise and complements its existing retinal R&D initiatives. Financial terms of the agreement were not disclosed. Following the announcement, GKOS stock lost 6.3% at yesterday's close, though it has gained 42.8% year to date, and the company currently has a market capitalization of $10.16 billion.

Glaukos Corp ▲